Archive ready
新型コロナウイルス治療薬の特例承認について｜厚生労働省
https://www.mhlw.go.jp/stf/newpage_21273.htmlApril 10, 2026 at 09:00 AM JST•The archive page, viewer, and downloads use this saved version.
April 10, 2026 at 09:00 AM JST·www.mhlw.go.jp
The evidence pack includes HTML, screenshots, summaries, and metadata. It can be downloaded on Pro.
Saved page
新型コロナウイルス治療薬の特例承認について｜厚生労働省
Open the archived HTML with saved-time metadata attached.
Original URLhttps://www.mhlw.go.jp/stf/newpage_21273.html
StartedApril 10, 2026 at 09:00 AM JST
This HTML has CSS and images embedded, so it can still be opened even if the original page disappears.
About this pageAI generated
This page announces the special approval of a COVID-19 therapeutic drug by the Ministry of Health, Labour and Welfare on September 27, 2021. Under Article 14-3 of the Pharmaceutical Affairs Law, GlaxoSmithKline K.K.'s "Zebuddy Intravenous Drip Injection 500mg" (generic name: Sotrovimab) has been granted special approval as a treatment for SARS-CoV-2 infection. The application was submitted on September 6, 2021.
